Impact socio-économique de la maladie d'alzheimer

et des maladies apparentées en europe

Translated title of the contribution: Socio-economic impact of alzheimer type diseases in europe

Paul Ariel Kenigsberg, Ersek Katalin, L. Gulácsi, Karpati Kristian, Alan Jacques, Gustavsson Anders, Linus Jönsson, McDaid David, Hannu Valtonen, Anders Wimo

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Cost assessment of Alzheimer's disease is a difficult task, all the more so when making a European comparison. How can costs be defined and measured when systems for taking charge of patients or reimbursements differ and when data in some countries are non-existent? The European Commission within the public health community action programme of 2003-2008 finances the European Collaboration on Dementia Socio-Economic Group. The programme was set up and coordinated by Alzheimer Europe and supported by the Alzheimer Médéric Foundation. The Group has created an economic model of the costs of the disease, making various assumptions, approximations and options based on identified economic data available in international literature. The total cost of Alzheimer's disease or diseases of the same type within Europe (UE 27) is estimated at 160.3 billion euros in 2008 (1.3% of the 2008 gross domestic product of UE 27), of which 71.7 billion in direct costs (45%) and 88.6 billion (55%) in indirect costs. The annual costs per person suffering from Alzheimer's disease are estimated at 22,194 euros of which 9,925 euros in direct costs and 12,270 euros in indirect costs. For the UE 27zone, the disease's load is estimated at 2.12 million years of DALY-disability adjusted life years (441 of DALY-disability adjusted life years for 100.000 people). This load is heavier than that of diabetes.

Original languageFrench
Pages (from-to)297-318
Number of pages22
JournalGerontologie et Societe
Volume128-129
Issue number1-2
Publication statusPublished - 2009

Fingerprint

economic impact
Alzheimer Disease
Economics
Disease
Costs and Cost Analysis
costs
dementia
Cost of Illness
Quality-Adjusted Life Years
Gross Domestic Product
Economic Models
disability
Dementia
gross domestic product
economic model
European Commission
Public Health
chronic illness
economics
finance

ASJC Scopus subject areas

  • Health(social science)
  • Gerontology
  • Geriatrics and Gerontology

Cite this

Kenigsberg, P. A., Katalin, E., Gulácsi, L., Kristian, K., Jacques, A., Anders, G., ... Wimo, A. (2009). Impact socio-économique de la maladie d'alzheimer: et des maladies apparentées en europe. Gerontologie et Societe, 128-129(1-2), 297-318.

Impact socio-économique de la maladie d'alzheimer : et des maladies apparentées en europe. / Kenigsberg, Paul Ariel; Katalin, Ersek; Gulácsi, L.; Kristian, Karpati; Jacques, Alan; Anders, Gustavsson; Jönsson, Linus; David, McDaid; Valtonen, Hannu; Wimo, Anders.

In: Gerontologie et Societe, Vol. 128-129, No. 1-2, 2009, p. 297-318.

Research output: Contribution to journalArticle

Kenigsberg, PA, Katalin, E, Gulácsi, L, Kristian, K, Jacques, A, Anders, G, Jönsson, L, David, M, Valtonen, H & Wimo, A 2009, 'Impact socio-économique de la maladie d'alzheimer: et des maladies apparentées en europe', Gerontologie et Societe, vol. 128-129, no. 1-2, pp. 297-318.
Kenigsberg PA, Katalin E, Gulácsi L, Kristian K, Jacques A, Anders G et al. Impact socio-économique de la maladie d'alzheimer: et des maladies apparentées en europe. Gerontologie et Societe. 2009;128-129(1-2):297-318.
Kenigsberg, Paul Ariel ; Katalin, Ersek ; Gulácsi, L. ; Kristian, Karpati ; Jacques, Alan ; Anders, Gustavsson ; Jönsson, Linus ; David, McDaid ; Valtonen, Hannu ; Wimo, Anders. / Impact socio-économique de la maladie d'alzheimer : et des maladies apparentées en europe. In: Gerontologie et Societe. 2009 ; Vol. 128-129, No. 1-2. pp. 297-318.
@article{2f0aff3a9491467ca0377e9adcd56b6e,
title = "Impact socio-{\'e}conomique de la maladie d'alzheimer: et des maladies apparent{\'e}es en europe",
abstract = "Cost assessment of Alzheimer's disease is a difficult task, all the more so when making a European comparison. How can costs be defined and measured when systems for taking charge of patients or reimbursements differ and when data in some countries are non-existent? The European Commission within the public health community action programme of 2003-2008 finances the European Collaboration on Dementia Socio-Economic Group. The programme was set up and coordinated by Alzheimer Europe and supported by the Alzheimer M{\'e}d{\'e}ric Foundation. The Group has created an economic model of the costs of the disease, making various assumptions, approximations and options based on identified economic data available in international literature. The total cost of Alzheimer's disease or diseases of the same type within Europe (UE 27) is estimated at 160.3 billion euros in 2008 (1.3{\%} of the 2008 gross domestic product of UE 27), of which 71.7 billion in direct costs (45{\%}) and 88.6 billion (55{\%}) in indirect costs. The annual costs per person suffering from Alzheimer's disease are estimated at 22,194 euros of which 9,925 euros in direct costs and 12,270 euros in indirect costs. For the UE 27zone, the disease's load is estimated at 2.12 million years of DALY-disability adjusted life years (441 of DALY-disability adjusted life years for 100.000 people). This load is heavier than that of diabetes.",
author = "Kenigsberg, {Paul Ariel} and Ersek Katalin and L. Gul{\'a}csi and Karpati Kristian and Alan Jacques and Gustavsson Anders and Linus J{\"o}nsson and McDaid David and Hannu Valtonen and Anders Wimo",
year = "2009",
language = "French",
volume = "128-129",
pages = "297--318",
journal = "Gerontologie et Societe",
issn = "0151-0193",
publisher = "Fondation Nationale de Gerontologie",
number = "1-2",

}

TY - JOUR

T1 - Impact socio-économique de la maladie d'alzheimer

T2 - et des maladies apparentées en europe

AU - Kenigsberg, Paul Ariel

AU - Katalin, Ersek

AU - Gulácsi, L.

AU - Kristian, Karpati

AU - Jacques, Alan

AU - Anders, Gustavsson

AU - Jönsson, Linus

AU - David, McDaid

AU - Valtonen, Hannu

AU - Wimo, Anders

PY - 2009

Y1 - 2009

N2 - Cost assessment of Alzheimer's disease is a difficult task, all the more so when making a European comparison. How can costs be defined and measured when systems for taking charge of patients or reimbursements differ and when data in some countries are non-existent? The European Commission within the public health community action programme of 2003-2008 finances the European Collaboration on Dementia Socio-Economic Group. The programme was set up and coordinated by Alzheimer Europe and supported by the Alzheimer Médéric Foundation. The Group has created an economic model of the costs of the disease, making various assumptions, approximations and options based on identified economic data available in international literature. The total cost of Alzheimer's disease or diseases of the same type within Europe (UE 27) is estimated at 160.3 billion euros in 2008 (1.3% of the 2008 gross domestic product of UE 27), of which 71.7 billion in direct costs (45%) and 88.6 billion (55%) in indirect costs. The annual costs per person suffering from Alzheimer's disease are estimated at 22,194 euros of which 9,925 euros in direct costs and 12,270 euros in indirect costs. For the UE 27zone, the disease's load is estimated at 2.12 million years of DALY-disability adjusted life years (441 of DALY-disability adjusted life years for 100.000 people). This load is heavier than that of diabetes.

AB - Cost assessment of Alzheimer's disease is a difficult task, all the more so when making a European comparison. How can costs be defined and measured when systems for taking charge of patients or reimbursements differ and when data in some countries are non-existent? The European Commission within the public health community action programme of 2003-2008 finances the European Collaboration on Dementia Socio-Economic Group. The programme was set up and coordinated by Alzheimer Europe and supported by the Alzheimer Médéric Foundation. The Group has created an economic model of the costs of the disease, making various assumptions, approximations and options based on identified economic data available in international literature. The total cost of Alzheimer's disease or diseases of the same type within Europe (UE 27) is estimated at 160.3 billion euros in 2008 (1.3% of the 2008 gross domestic product of UE 27), of which 71.7 billion in direct costs (45%) and 88.6 billion (55%) in indirect costs. The annual costs per person suffering from Alzheimer's disease are estimated at 22,194 euros of which 9,925 euros in direct costs and 12,270 euros in indirect costs. For the UE 27zone, the disease's load is estimated at 2.12 million years of DALY-disability adjusted life years (441 of DALY-disability adjusted life years for 100.000 people). This load is heavier than that of diabetes.

UR - http://www.scopus.com/inward/record.url?scp=70349318042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349318042&partnerID=8YFLogxK

M3 - Article

VL - 128-129

SP - 297

EP - 318

JO - Gerontologie et Societe

JF - Gerontologie et Societe

SN - 0151-0193

IS - 1-2

ER -